David A Tuveson

List of Publications by Year
in descending order

163 papers	61,138 citations	4345 89 h-index	6349 163 g-index
174 all docs	174 docs citations	174 times ranked	61154 citing authors

#	Article	IF	Citations
1	Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. Gut, 2022, 71, 879-888.	6.1	24
2	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Research, 2022, 82, 1174-1192.	0.4	21
3	Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Clinical Cancer Research, 2022, 28, 3296-3307.	3.2	27
4	Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-NeedleÂBiopsy Sample Collection for Creation ofÂPancreatic Adenocarcinoma Organoids. Clinical Gastroenterology and Hepatology, 2021, 19, 845-847.	2.4	18
5	Diversity and Biology of Cancer-Associated Fibroblasts. Physiological Reviews, 2021, 101, 147-176.	13.1	521
6	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research, 2021, 27, 226-236.	3.2	15
7	Fighting the Sixth Decade of the Cancer War with Better Cancer Models. Cancer Discovery, 2021, 11, 801-804.	7.7	5
8	Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
9	Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nature Communications, 2021, 12, 3414.	5.8	65
10	Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 2023-2037.	3.2	156
11	Impact of COVID-19 Pandemic on Cancer Research. Cancer Cell, 2020, 38, 591-593.	7.7	7
12	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Cancer Discovery, 2020, 10, 1566-1589.	7.7	90
13	SIRT1â€“NOX4 signaling axis regulates cancer cachexia. Journal of Experimental Medicine, 2020, 217, .	4.2	43
14	Pancreatic cancer SLUGged. Journal of Experimental Medicine, 2020, 217, .	4.2	0
15	SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	65
16	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	2.1	61
17	Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, 69, 1592-1597.	6.1	106
18	Cancer Cellâ€“Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2020, 80, 1461-1474.	0.4	99

#	Article	IF	Citations
19	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	13.7	229
20	Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics, 2020, 52, 231-240.	9.4	365
21	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
22	Securing the future of the clinician-scientist. Nature Cancer, 2020, 1, 139-141.	5.7	20
23	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	13.5	182
24	Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, 159, 1129-1131.e3.	0.6	214
25	Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget, 2020, 11, 3621-3632.	0.8	29
26	Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. ELife, 2020, 9, .	2.8	61
27	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. ELife, 2020, 9, .	2.8	61
28	Immigration in science. Journal of Experimental Medicine, 2020, 217, .	4.2	2
29	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene, 2019, 38, 5890-5904.	2.6	63
30	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	1.5	14
31	Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discovery, 2019, 9, 1268-1287.	7.7	119
32	Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Reports, 2019, 29, 1287-1298.e6.	2.9	105
33	Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19609-19618.	3.3	244
34	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6742-6755.	3.2	45
35	Bioactivation of Napabucasin Triggers Reactive Oxygen Speciesâ€“Mediated Cancer Cell Death. Clinical Cancer Research, 2019, 25, 7162-7174.	3.2	46
36	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science, 2019, 364, 1156-1162.	6.0	166

#	Article	IF	Citations
37	Cancer modeling meets human organoid technology. Science, 2019, 364, 952-955.	6.0	577
38	Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discovery, 2019, 9, 1102-1123.	7.7	1,120
39	A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth. Cancer Discovery, 2019, 9, 578-580.	7.7	7
40	Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discovery, 2019, 9, 852-871.	7.7	222
41	Organoid Models for Cancer Research. Annual Review of Cancer Biology, 2019, 3, 223-234.	2.3	44
42	Organoid models for translational pancreatic cancer research. Current Opinion in Genetics and Development, 2019, 54, 7-11.	1.5	57
43	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. Gut, 2019, 68, 159-171.	6.1	246
44	IL1-Induced JAK/STAT Signaling Is Antagonized by TGFÎ² to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discovery, 2019, 9, 282-301.	7.7	778
45	Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma. Methods in Molecular Biology, 2019, 1882, 117-133.	0.4	8
46	Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. Methods in Molecular Biology, 2019, 1882, 97-115.	0.4	26
47	Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening. SLAS Discovery, 2018, 23, 574-584.	1.4	119
48	Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointestinal Endoscopy, 2018, 87, 1474-1480.	0.5	126
49	A phase I trial of the Î³-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	2.9	90
50	Kras in Organoids. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031575.	2.9	4
51	Transcriptional Regulation by Nrf2. Antioxidants and Redox Signaling, 2018, 29, 1727-1745.	2.5	1,356
52	Deciphering cancer fibroblasts. Journal of Experimental Medicine, 2018, 215, 2967-2968.	4.2	28
53	Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Research, 2018, 78, 4253-4269.	0.4	105
54	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	7.7	676

#	Article	IF	Citations
55	Pancreatic cancer foiled by a switch of tumour subtype. Nature, 2018, 557, 500-501.	13.7	8
56	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	7.7	256
57	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	0.8	21
58	Untangling the genetics from the epigenetics in pancreatic cancer metastasis. Nature Genetics, 2017, 49, 323-324.	9.4	16
59	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental Medicine, 2017, 214, 579-596.	4.2	1,582
60	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 2017, 49, 825-833.	9.4	55
61	111 Successful Creation of Pancreatic Cancer Organoids By Means of Eus-Guided Fine-Needle Biopsy (EUS-FNB) for Personalized Cancer Treatment. Gastrointestinal Endoscopy, 2017, 85, AB50-AB51.	0.5	5
62	PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. Cancer Research, 2017, 77, 1868-1879.	0.4	67
63	Soils and Seeds That Initiate Pancreatic Cancer Metastasis. Cancer Discovery, 2017, 7, 1067-1068.	7.7	5
64	Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell, 2017, 170, 875-888.e20.	13.5	339
65	Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells. PLoS ONE, 2016, 11, e0148055.	1.1	11
66	Challenges and Opportunities in Modeling Pancreatic Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 231-235.	2.0	8
67	Modeling Pancreatic Cancer with Organoids. Trends in Cancer, 2016, 2, 176-190.	3.8	174
68	Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology, 2016, 18, 549-560.	4.6	329
69	NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Cell, 2016, 166, 963-976.	13.5	294
70	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Research, 2016, 76, 6851-6863.	0.4	209
71	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	18.1	1,301
72	MRI with hyperpolarised [1-¹³C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut, 2016, 65, 465-475.	6.1	71

#	Article	IF	Citations
73	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	3.2	69
74	Model organoids provide new research opportunities for ductal pancreatic cancer. Molecular and Cellular Oncology, 2016, 3, e1014757.	0.3	52
75	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget, 2016, 7, 33529-33541.	0.8	21
76	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E536-45.	3.3	121
77	Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut, 2015, 64, 1476-1484.	6.1	444
78	Augmenting NF-ÎºB in poor-risk CLL: A general paradigm for other cancers?. Journal of Experimental Medicine, 2015, 212, 830-831.	4.2	5
79	Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 2015, 160, 324-338.	13.5	1,584
80	The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell, 2015, 162, 259-270.	13.5	359
81	TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. Journal of Experimental Medicine, 2015, 212, 2077-2094.	4.2	142
82	Impaired JNK Signaling Cooperates with <i>KrasG12D</i> Expression to Accelerate Pancreatic Ductal Adenocarcinoma. Cancer Research, 2014, 74, 3344-3356.	0.4	26
83	SPARC independent drug delivery and antitumour effects of<i>nab</i>-paclitaxel in genetically engineered mice. Gut, 2014, 63, 974-983.	6.1	125
84	Inflammation-Induced NFATc1â€“STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by <i>Kras</i>G12D. Cancer Discovery, 2014, 4, 688-701.	7.7	108
85	Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine, 2014, 211, 1503-1523.	4.2	683
86	Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell, 2014, 159, 80-93.	13.5	871
87	The Promise and Perils of Antioxidants for Cancer Patients. New England Journal of Medicine, 2014, 371, 177-178.	13.9	169
88	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with antiâ€“PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20212-20217.	3.3	1,482
89	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 2013, 62, 112-120.	6.1	866
90	Recapitulating human cancer in a mouse. Nature Biotechnology, 2013, 31, 392-395.	9.4	7

#	Article	IF	Citations
91	Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut, 2013, 62, 1034-1043.	6.1	67
92	Depletion of stromal cells expressing fibroblast activation protein-Î± from skeletal muscle and bone marrow results in cachexia and anemia. Journal of Experimental Medicine, 2013, 210, 1137-1151.	4.2	304
93	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12325-12330.	3.3	207
94	Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS ONE, 2013, 8, e67330.	1.1	29
95	RhoC Interacts with Integrin Î±5Î²1 and Enhances Its Trafficking in Migrating Pancreatic Carcinoma Cells. PLoS ONE, 2013, 8, e81575.	1.1	20
96	<i>nab</i>-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2012, 2, 260-269.	7.7	359
97	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Journal of Experimental Medicine, 2012, 209, 437-444.	4.2	92
98	The Pancreas Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 4266-4276.	3.2	1,087
99	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	13.7	297
100	Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut, 2012, 61, 877-884.	6.1	68
101	Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology, 2012, 12, 8-15.	0.5	49
102	Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches. Cell, 2012, 148, 21-23.	13.5	166
103	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	13.7	1,741
104	Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today, 2012, 17, 253-260.	3.2	92
105	Retinoic Acidâ€"Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wntâ€"Î²-Catenin Signaling to Slow Tumor Progression. Gastroenterology, 2011, 141, 1486-1497.e14.	0.6	316
106	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475, 106-109.	13.7	1,831
107	InÂVivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell, 2011, 147, 382-395.	13.5	602
108	Stromal biology and therapy in pancreatic cancer. Gut, 2011, 60, 861-868.	6.1	652

#	Article	IF	Citations
109	Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature, 2011, 469, 539-542.	13.7	1,127
110	Cancer lessons from mice to humans. Nature, 2011, 471, 316-317.	13.7	80
111	A novel method for quantification of gemcitabine and its metabolites 2â€²,2â€²-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LCâ€"MS/MS: comparison with 19F NMR spectroscopy. Cancer Chemotherapy and Pharmacology, 2011, 68, 1243-1253.	1.1	48
112	C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D. Cancer Discovery, 2011, 1, 128-136.	7.7	126
113	Crosstalk between the canonical NF-ÎºB and Notch signaling pathways inhibits PparÎ³ expression and promotes pancreatic cancer progression in mice. Journal of Clinical Investigation, 2011, 121, 4685-4699.	3.9	213
114	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	3.9	153
115	Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer. Cancer Cell, 2010, 18, 499-509.	7.7	147
116	Deploying Mouse Models of Pancreatic Cancer for Chemoprevention Studies. Cancer Prevention Research, 2010, 3, 1382-1387.	0.7	27
117	Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Proteinâ€"Î±. Science, 2010, 330, 827-830.	6.0	952
118	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	6.0	2,730
119	An shRNA silencing a nonâ€toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. Journal of Cellular Physiology, 2009, 219, 365-371.	2.0	6
120	Modelling oncogenic Ras/Raf signalling in the mouse. Current Opinion in Genetics and Development, 2009, 19, 4-11.	1.5	55
121	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. Molecular Cell, 2009, 36, 477-486.	4.5	61
122	The use of GEM models for experimental cancer therapeutics. DMM Disease Models and Mechanisms, 2008, 1, 83-86.	1.2	47
123	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research, 2008, 14, 4836-4842.	3.2	136
124	Kâ€Rasâ€Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor Analyses. Methods in Enzymology, 2008, 439, 73-85.	0.4	26
125	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 2007, 21, 694-707.	2.7	120
126	The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression. Cancer Research, 2007, 67, 6075-6082.	0.4	108

#	Article	IF	Citations
127	Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion. Cancer Research, 2007, 67, 9518-9527.	0.4	838
128	Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood, 2007, 109, 5238-5241.	0.6	26
129	Requirement for Rac1 in a K-rasâ€"Induced Lung Cancer in the Mouse. Cancer Research, 2007, 67, 8089-8094.	0.4	148
130	Maximizing mouse cancer models. Nature Reviews Cancer, 2007, 7, 654-658.	12.8	617
131	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	13.7	1,662
132	KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas. Cancer Cell, 2007, 11, 229-243.	7.7	327
133	Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885. Cancer Research, 2006, 66, 11100-11105.	0.4	257
134	Physiological Analysis of Oncogenic Kâ€Ras. Methods in Enzymology, 2006, 407, 676-690.	0.4	19
135	Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations. Cancer Research, 2006, 66, 95-106.	0.4	401
136	Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. Cancer Research, 2006, 66, 242-247.	0.4	132
137	The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics. Clinical Cancer Research, 2006, 12, 5277-5287.	3.2	218
138	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	7.7	2,137
139	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.4	488
140	Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors. Cancer Research, 2005, 65, 2412-2421.	0.4	296
141	Mice Expressing a Mammary Glandâ€"Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.4	59
142	VAV1: A new target in pancreatic cancer?. Cancer Biology and Therapy, 2005, 4, 509-511.	1.5	18
143	ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8, 311-321.	7.7	866
144	Detecting and diagnosing ampullary neoplasms. Cancer Biology and Therapy, 2004, 3, 657-659.	1.5	5

#	ARTICLE	IF	CITATIONS
145	Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biology and Therapy, 2004, 3, 1058-1059.	1.5	78
146	Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 597-602.	3.3	279
147	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	7.7	710
148	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	13.5	1,140
149	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Journal of Clinical Investigation, 2004, 113, 528-538.	3.9	231
150	Targeting oncogene dependence and resistance. Cancer Cell, 2003, 3, 414-417.	7.7	26
151	BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell, 2003, 4, 95-98.	7.7	154
152	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	7.7	2,150
153	Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes and Development, 2003, 17, 3112-3126.	2.7	912
154	Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics and Development, 2003, 13, 6-13.	1.5	80
155	Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research, 2003, 63, 5198-202.	0.4	337
156	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	13.9	4,018
157	Technologically advanced cancer modeling in mice. Current Opinion in Genetics and Development, 2002, 12, 105-110.	1.5	77
158	Signal transduction pathways in sarcoma as targets for therapeutic intervention. Current Opinion in Oncology, 2001, 13, 249-255.	1.1	28
159	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	2.6	643
160	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	13.7	1,060
161	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 2001, 15, 3243-3248.	2.7	1,663
162	Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine, 2001, 344, 1052-1056.	13.9	1,926

#	Article	IF	Citations
163	Modeling human lung cancer in mice: similarities and shortcomings. Oncogene, 1999, 18, 5318-5324.	2.6	121